Middle East Respiratory Syndrome (MERS) coronavirus (MERS-CoV) causes severe acute respiratory illness with a high fatality rate among reported cases. MERS was first reported in 2012, but the virus has been circulating in camels, which are thought to be an animal reservoir, for at least 20 years. To date over 1000 MERS cases have been reported to the World Health Organization, including over 400 deaths. While most cases have been in Saudi Arabia and contact with camels or camel products has been implicated in some cases, human-to-human transmission has been documented as well and the virus is thought to have epidemic potential. There are currently no approved vaccines or therapeutics for MERS. The MERS-CoV spike (S) protein mediates viral entry into host cells expressing the viral receptor dipeptidyl peptidase 4 (DPP4). Within the S1 subunit, a Receptor Binding Domain (RBD) of about 200 amino acids has been identified. Immunization of mice with a recombinant fusion protein containing S377-588 fused to human IgG1 Fc (S377-588-Fc) induced high titers of neutralizing antibodies in immunized animals. Unfortunately, expression of S377-588-Fc (or RBD-Fc) in mammalian cell culture is low, which may be an impediment for further development of this promising candidate vaccine. We will circumvent the production problem by producing MERS-CoV RBD-Fc, and modifications thereof, using a well-established plant-expression system. Our scalable transient plant-expression system allows rapid production of recombinant protein (within a week); with protein production costs less than 10% that of mammalian cell systems. We will produce variants of MERS-CoV RBD-Fc with enhanced binding to the mouse neonatal Fc receptor (FcRn), in order to test the hypothesis that improved antigen presentation via FcRn will result in an enhanced immune response. We will evaluate the immunogenicity of mucosally-administered MERS-CoV RBD-Fc in mice, by analyzing both humoral and cell-mediated immunity. We will evaluate titers of RBD-specific antibodies, analyze T cell responses by intracellular cytokine staining followed by flow cytometry analysis, and will measure the ability of sera from immunized mice to neutralize live MERS-CoV in vitro.

Public Health Relevance

Middle East respiratory syndrome coronavirus (MERS-CoV), also termed hCoV-EMC, was first identified in humans in 2012 in the Middle East. To date >1000 people have contracted MERS in 22 countries, resulting in >400 deaths. Epidemiology studies suggest human-to-human transmission of this deadly virus, leading to concern about a MERS pandemic. Using a plant expression system we will develop an effective MERS-CoV vaccine designed to be delivered to mucosal surfaces.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI122551-01A1
Application #
9141182
Study Section
Special Emphasis Panel (ZRG1-IMM-R (12)B)
Program Officer
Stemmy, Erik J
Project Start
2017-02-17
Project End
2018-02-16
Budget Start
2017-02-17
Budget End
2018-02-16
Support Year
1
Fiscal Year
2017
Total Cost
$236,488
Indirect Cost
Name
Planet Biotechnology, Inc.
Department
Type
Domestic for-Profits
DUNS #
052917593
City
Hayward
State
CA
Country
United States
Zip Code
94545